Literature DB >> 28566477

Long-Term Outcome of Steroid-Resistant Nephrotic Syndrome in Children.

Agnes Trautmann1, Sven Schnaidt2, Beata S Lipska-Ziętkiewicz3, Monica Bodria4,5, Fatih Ozaltin6, Francesco Emma7, Ali Anarat8, Anette Melk9, Marta Azocar10, Jun Oh11, Bassam Saeed12, Alaleh Gheisari13, Salim Caliskan14, Jutta Gellermann15, Lina Maria Serna Higuita16, Augustina Jankauskiene17, Dorota Drozdz18, Sevgi Mir19, Ayse Balat20, Maria Szczepanska21, Dusan Paripovic22, Alexandra Zurowska23, Radovan Bogdanovic24, Alev Yilmaz25, Bruno Ranchin26, Esra Baskin27, Ozlem Erdogan28, Giuseppe Remuzzi29,30,31, Agnieszka Firszt-Adamczyk32, Elzbieta Kuzma-Mroczkowska33, Mieczyslaw Litwin34, Luisa Murer35, Marcin Tkaczyk36, Helena Jardim37, Anna Wasilewska38, Nikoleta Printza39, Kibriya Fidan40, Eva Simkova41, Halina Borzecka42, Hagen Staude43, Katharina Hees2, Franz Schaefer44.   

Abstract

We investigated the value of genetic, histopathologic, and early treatment response information in prognosing long-term renal outcome in children with primary steroid-resistant nephrotic syndrome. From the PodoNet Registry, we obtained longitudinal clinical information for 1354 patients (disease onset at >3 months and <20 years of age): 612 had documented responsiveness to intensified immunosuppression (IIS), 1155 had kidney biopsy results, and 212 had an established genetic diagnosis. We assessed risk factors for ESRD using multivariate Cox regression models. Complete and partial remission of proteinuria within 12 months of disease onset occurred in 24.5% and 16.5% of children, respectively, with the highest remission rates achieved with calcineurin inhibitor-based protocols. Ten-year ESRD-free survival rates were 43%, 94%, and 72% in children with IIS resistance, complete remission, and partial remission, respectively; 27% in children with a genetic diagnosis; and 79% and 52% in children with histopathologic findings of minimal change glomerulopathy and FSGS, respectively. Five-year ESRD-free survival rate was 21% for diffuse mesangial sclerosis. IIS responsiveness, presence of a genetic diagnosis, and FSGS or diffuse mesangial sclerosis on initial biopsy as well as age, serum albumin concentration, and CKD stage at onset affected ESRD risk. Our findings suggest that responsiveness to initial IIS and detection of a hereditary podocytopathy are prognostic indicators of favorable and poor long-term outcome, respectively, in children with steroid-resistant nephrotic syndrome. Children with multidrug-resistant sporadic disease show better renal survival than those with genetic disease. Furthermore, histopathologic findings may retain prognostic relevance when a genetic diagnosis is established.
Copyright © 2017 by the American Society of Nephrology.

Entities:  

Keywords:  children; immunosuppression; nephrotic syndrome; outcomes; podocytopathies; steroid resistance

Mesh:

Substances:

Year:  2017        PMID: 28566477      PMCID: PMC5619960          DOI: 10.1681/ASN.2016101121

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  37 in total

1.  Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort.

Authors:  Agnes Trautmann; Monica Bodria; Fatih Ozaltin; Alaleh Gheisari; Anette Melk; Marta Azocar; Ali Anarat; Salim Caliskan; Francesco Emma; Jutta Gellermann; Jun Oh; Esra Baskin; Joanna Ksiazek; Giuseppe Remuzzi; Ozlem Erdogan; Sema Akman; Jiri Dusek; Tinatin Davitaia; Ozan Özkaya; Fotios Papachristou; Agnieszka Firszt-Adamczyk; Tomasz Urasinski; Sara Testa; Rafael T Krmar; Lidia Hyla-Klekot; Andrea Pasini; Z Birsin Özcakar; Peter Sallay; Nilgun Cakar; Monica Galanti; Joelle Terzic; Bilal Aoun; Alberto Caldas Afonso; Hanna Szymanik-Grzelak; Beata S Lipska; Sven Schnaidt; Franz Schaefer
Journal:  Clin J Am Soc Nephrol       Date:  2015-01-29       Impact factor: 8.237

2.  Predictive factors of chronic kidney disease in primary focal segmental glomerulosclerosis.

Authors:  Marcelo M Abrantes; Luis Sergio B Cardoso; Eleonora M Lima; José M Penido Silva; José S Diniz; Eduardo A Bambirra; Eduardo A Oliveira
Journal:  Pediatr Nephrol       Date:  2006-05-30       Impact factor: 3.714

3.  Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children.

Authors:  P Tarshish; J N Tobin; J Bernstein; C M Edelmann
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

4.  Primary focal segmental glomerulosclerosis in children: prognostic factors.

Authors:  R Martinelli; A S Okumura; L J Pereira; H Rocha
Journal:  Pediatr Nephrol       Date:  2001-08       Impact factor: 3.714

5.  Cyclosporine in patients with steroid-resistant nephrotic syndrome: an open-label, nonrandomized, retrospective study.

Authors:  Gian Marco Ghiggeri; Paolo Catarsi; Francesco Scolari; Gianluca Caridi; Roberta Bertelli; Alba Carrea; Simone Sanna-Cherchi; Francesco Emma; Landino Allegri; Giovanni Cancarini; Gian Franco Rizzoni; Francesco Perfumo
Journal:  Clin Ther       Date:  2004-09       Impact factor: 3.393

Review 6.  Interventions for idiopathic steroid-resistant nephrotic syndrome in children.

Authors:  Elisabeth M Hodson; Narelle S Willis; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2010-11-10

7.  Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome.

Authors:  Zhihui Li; Cuirong Duan; Jinhua He; Tianhui Wu; Mai Xun; Yi Zhang; Yan Yin
Journal:  Pediatr Nephrol       Date:  2009-12-02       Impact factor: 3.714

8.  Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome.

Authors:  Rainer G Ruf; Anne Lichtenberger; Stephanie M Karle; Johannes P Haas; Franzisco E Anacleto; Michael Schultheiss; Isabella Zalewski; Anita Imm; Eva-Maria Ruf; Bettina Mucha; Arvind Bagga; Thomas Neuhaus; Arno Fuchshuber; Aysin Bakkaloglu; Friedhelm Hildebrandt
Journal:  J Am Soc Nephrol       Date:  2004-03       Impact factor: 10.121

9.  Rapid Response to Cyclosporin A and Favorable Renal Outcome in Nongenetic Versus Genetic Steroid-Resistant Nephrotic Syndrome.

Authors:  Anja K Büscher; Bodo B Beck; Anette Melk; Julia Hoefele; Birgitta Kranz; Daniel Bamborschke; Sabrina Baig; Bärbel Lange-Sperandio; Theresa Jungraithmayr; Lutz T Weber; Markus J Kemper; Burkhard Tönshoff; Peter F Hoyer; Martin Konrad; Stefanie Weber
Journal:  Clin J Am Soc Nephrol       Date:  2015-12-14       Impact factor: 8.237

10.  The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A.

Authors:  Christian Faul; Mary Donnelly; Sandra Merscher-Gomez; Yoon Hee Chang; Stefan Franz; Jacqueline Delfgaauw; Jer-Ming Chang; Hoon Young Choi; Kirk N Campbell; Kwanghee Kim; Jochen Reiser; Peter Mundel
Journal:  Nat Med       Date:  2008-09       Impact factor: 53.440

View more
  52 in total

Review 1.  Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children.

Authors:  Koichi Kamei; Kenji Ishikura; Mayumi Sako; Shuichi Ito; Kandai Nozu; Kazumoto Iijima
Journal:  Pediatr Nephrol       Date:  2018-12-18       Impact factor: 3.714

Review 2.  The status quo and challenges of genetic diagnosis in children with steroid-resistant nephrotic syndrome.

Authors:  Yan-Yan Jin; Bing-Yu Feng; Jian-Hua Mao
Journal:  World J Pediatr       Date:  2018-04-11       Impact factor: 2.764

3.  Genetic variants in the LAMA5 gene in pediatric nephrotic syndrome.

Authors:  Daniela A Braun; Jillian K Warejko; Shazia Ashraf; Weizhen Tan; Ankana Daga; Ronen Schneider; Tobias Hermle; Tilman Jobst-Schwan; Eugen Widmeier; Amar J Majmundar; Makiko Nakayama; David Schapiro; Jia Rao; Johanna Magdalena Schmidt; Charlotte A Hoogstraten; Hannah Hugo; Sevcan A Bakkaloglu; Jameela A Kari; Sherif El Desoky; Ghaleb Daouk; Shrikant Mane; Richard P Lifton; Shirlee Shril; Friedhelm Hildebrandt
Journal:  Nephrol Dial Transplant       Date:  2019-03-01       Impact factor: 5.992

4.  Mutations in multiple components of the nuclear pore complex cause nephrotic syndrome.

Authors:  Daniela A Braun; Svjetlana Lovric; David Schapiro; Ronen Schneider; Jonathan Marquez; Maria Asif; Muhammad Sajid Hussain; Ankana Daga; Eugen Widmeier; Jia Rao; Shazia Ashraf; Weizhen Tan; C Patrick Lusk; Amy Kolb; Tilman Jobst-Schwan; Johanna Magdalena Schmidt; Charlotte A Hoogstraten; Kaitlyn Eddy; Thomas M Kitzler; Shirlee Shril; Abubakar Moawia; Kathrin Schrage; Arwa Ishaq A Khayyat; Jennifer A Lawson; Heon Yung Gee; Jillian K Warejko; Tobias Hermle; Amar J Majmundar; Hannah Hugo; Birgit Budde; Susanne Motameny; Janine Altmüller; Angelika Anna Noegel; Hanan M Fathy; Daniel P Gale; Syeda Seema Waseem; Ayaz Khan; Larissa Kerecuk; Seema Hashmi; Nilufar Mohebbi; Robert Ettenger; Erkin Serdaroğlu; Khalid A Alhasan; Mais Hashem; Sara Goncalves; Gema Ariceta; Mercedes Ubetagoyena; Wolfram Antonin; Shahid Mahmood Baig; Fowzan S Alkuraya; Qian Shen; Hong Xu; Corinne Antignac; Richard P Lifton; Shrikant Mane; Peter Nürnberg; Mustafa K Khokha; Friedhelm Hildebrandt
Journal:  J Clin Invest       Date:  2018-09-04       Impact factor: 14.808

Review 5.  Immunopathogenesis of idiopathic nephrotic syndrome in children: two sides of the coin.

Authors:  Jing Chen; Xiao-Hui Qiao; Jian-Hua Mao
Journal:  World J Pediatr       Date:  2021-03-03       Impact factor: 2.764

Review 6.  Treatment of nephrotic syndrome: going beyond immunosuppressive therapy.

Authors:  Jinghong Zhao; Zhihong Liu
Journal:  Pediatr Nephrol       Date:  2019-03-23       Impact factor: 3.714

7.  De novo TRIM8 variants impair its protein localization to nuclear bodies and cause developmental delay, epilepsy, and focal segmental glomerulosclerosis.

Authors:  Patricia L Weng; Amar J Majmundar; Kamal Khan; Tze Y Lim; Shirlee Shril; Gina Jin; John Musgrove; Minxian Wang; Dina F Ahram; Vimla S Aggarwal; Louise E Bier; Erin L Heinzen; Ana C Onuchic-Whitford; Nina Mann; Florian Buerger; Ronen Schneider; Konstantin Deutsch; Thomas M Kitzler; Verena Klämbt; Amy Kolb; Youying Mao; Christelle Moufawad El Achkar; Adele Mitrotti; Jeremiah Martino; Bodo B Beck; Janine Altmüller; Marcus R Benz; Shoji Yano; Mohamad A Mikati; Talha Gunduz; Heidi Cope; Vandana Shashi; Howard Trachtman; Monica Bodria; Gianluca Caridi; Isabella Pisani; Enrico Fiaccadori; Asmaa S AbuMaziad; Julian A Martinez-Agosto; Ora Yadin; Jonathan Zuckerman; Arang Kim; Ulrike John-Kroegel; Amanda V Tyndall; Jillian S Parboosingh; A Micheil Innes; Agnieszka Bierzynska; Ania B Koziell; Mordi Muorah; Moin A Saleem; Julia Hoefele; Korbinian M Riedhammer; Ali G Gharavi; Vaidehi Jobanputra; Emma Pierce-Hoffman; Eleanor G Seaby; Anne O'Donnell-Luria; Heidi L Rehm; Shrikant Mane; Vivette D D'Agati; Martin R Pollak; Gian Marco Ghiggeri; Richard P Lifton; David B Goldstein; Erica E Davis; Friedhelm Hildebrandt; Simone Sanna-Cherchi
Journal:  Am J Hum Genet       Date:  2021-01-27       Impact factor: 11.025

Review 8.  Treatment of steroid-resistant nephrotic syndrome in the genomic era.

Authors:  Adam R Bensimhon; Anna E Williams; Rasheed A Gbadegesin
Journal:  Pediatr Nephrol       Date:  2018-10-02       Impact factor: 3.714

9.  Reverse Phenotyping after Whole-Exome Sequencing in Steroid-Resistant Nephrotic Syndrome.

Authors:  Samuela Landini; Benedetta Mazzinghi; Francesca Becherucci; Marco Allinovi; Aldesia Provenzano; Viviana Palazzo; Fiammetta Ravaglia; Rosangela Artuso; Emanuele Bosi; Stefano Stagi; Giulia Sansavini; Francesco Guzzi; Luigi Cirillo; Augusto Vaglio; Luisa Murer; Licia Peruzzi; Andrea Pasini; Marco Materassi; Rosa Maria Roperto; Hans-Joachim Anders; Mario Rotondi; Sabrina Rita Giglio; Paola Romagnani
Journal:  Clin J Am Soc Nephrol       Date:  2019-12-12       Impact factor: 8.237

Review 10.  Podocytopathies.

Authors:  Jeffrey B Kopp; Hans-Joachim Anders; Katalin Susztak; Manuel A Podestà; Giuseppe Remuzzi; Friedhelm Hildebrandt; Paola Romagnani
Journal:  Nat Rev Dis Primers       Date:  2020-08-13       Impact factor: 52.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.